Methods for treating radiation or chemical injury

Abstract

Methods for treating radiation or chemical injury are described that comprise administering to a subject a therapeutically effective amount of adherent stromal cells. Methods of preparing adherent stromal cells and pharmaceutical compositions comprising the cells are also described.

1 .- 126 . (canceled) 
     
     
         127 . A method of mitigating reduction, resulting from exposure to radiation, in a subject's number of endogenous hematopoietic cells, comprising administering to said subject a composition comprising adherent stromal cells (ASC), wherein the ASC are administered before said exposure, and wherein the ASC were cultured under three-dimensional culturing conditions. 
     
     
         128 . The method of  claim 127 , wherein said ASC are administered by intramuscular injection. 
     
     
         129 . The method of  claim 127 , wherein the origin of the ASC is placenta. 
     
     
         130 . The method of  claim 129 , where at least 50% of the ASC are fetal cells. 
     
     
         131 . The method of  claim 127 , wherein the origin of the ASC is selected from adipose tissue and bone marrow. 
     
     
         132 . The method of  claim 127 , wherein said three-dimensional culturing conditions comprise culturing in a bioreactor. 
     
     
         133 . The method of  claim 127 , wherein at least 70% of the ASC are positive for the marker CD200, as detected by flow cytometry compared to an isotype control. 
     
     
         134 . The method of  claim 127 , wherein the ASC are administered 1 day before said exposure. 
     
     
         135 . A method of mitigating reduction, resulting from exposure to a chemical, in a subject's number of endogenous hematopoietic cells, comprising administering to said subject a composition comprising adherent stromal cells (ASC), wherein the ASC are administered before said exposure, and wherein the ASC were cultured under three-dimensional culturing conditions. 
     
     
         136 . The method of  claim 135 , wherein said ASC are administered by intramuscular injection. 
     
     
         137 . The method of  claim 135 , wherein the origin of the ASC is placenta. 
     
     
         138 . The method of  claim 137 , where at least 50% of the ASC are fetal cells. 
     
     
         139 . The method of  claim 135 , wherein the origin of the ASC is selected from adipose tissue and bone marrow. 
     
     
         140 . The method of  claim 135 , wherein said three-dimensional culturing conditions comprise culturing in a bioreactor. 
     
     
         141 . The method of  claim 135 , wherein at least 70% of the ASC are positive for the marker CD200, as detected by flow cytometry compared to an isotype control. 
     
     
         142 . The method of  claim 135 , wherein the ASC are administered 1 day before said exposure. 
     
     
         143 . The method of  claim 135 , wherein said chemical is a chemotherapy agent. 
     
     
         144 . A method of reducing a symptom associated with radiation sickness in a subject, comprising administering to said subject a composition comprising adherent stromal cells (ASC), wherein the ASC are administered before exposure to radiation, and wherein the ASC were cultured under three-dimensional culturing conditions. 
     
     
         145 . The method of  claim 144 , wherein said symptom is selected from leukopenia, anemia, thrombocytopenia, nausea, vomiting, and diarrhea. 
     
     
         146 . The method of  claim 144 , wherein said ASC are administered by intramuscular injection.